Medication info
Memantine Tablet 10 mg (Memantine Hydrochloride)

Memantine Tablet 10 mg (Memantine Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Memantine Hydrochloride›10mg / 1 tablet
Manufacturer / importer
CMG Pharmaceutical Co., Ltd.
Appearance
White oblong film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201601008 · Approved 2016.02.24 · Insurance code 648603220

Summary

Main use
Treatment of moderate to severe Alzheimer's disease
Who takes it
Adults
Adult dose
Treatment must be initiated by a physician experienced in the diagnosis and treatment of Alzheimer’s dementia, and only if a caregiver is available to regularly verify that the patient is taking the medicine. Diagnosis should be made according to currently accepted guidelines. The clinical benefit of this medicine and the patient’s tolerability of treatment should be reassessed regularly. This medicine may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20 mg. To minimize the risk of adverse reactions, increase the dose by 5 mg per week over the first 3 weeks as follows, until the maintenance dose is reached. Week 1 (Days 1–7): Administer 5 mg once daily for 7 days. Week 2 (Days 8–14): Administer 10 mg daily (5 mg twice daily) for 7 days. Week 3 (Days 15–21): Administer 15 mg daily (10 mg in the morning and 5 mg in the evening) for 7 days. From Week 4 onward: Administer 20 mg daily (10 mg twice daily). Maintenance dose: The recommended maintenance dose is 20 mg daily (10 mg twice daily). 2. Older adults: Based on clinical data, the recommended dose in patients 65 years of age and older is 20 mg daily (10 mg twice daily). 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-50 mL/min), the daily dose should be reduced to 10 mg. If well tolerated, the dose may be increased to 20 mg daily according to the standard dose escalation schedule after at least 7 days of treatment. In patients with severe renal impairment (creatinine clearance 5-30 mL/min), the daily dose should be reduced to 10 mg. 4. Patients with hepatic impairment: No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since no data are available on the use of memantine in patients with severe hepatic impairment, administration of this medicine is not recommended.

Ingredients

Manufacturer
CMG Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of moderate to severe Alzheimer's disease

  • Alzheimer's disease
View approved original text

This medicine is used for the treatment of moderate to severe Alzheimer's disease.

How to take

Adult dose

Treatment must be initiated by a physician experienced in the diagnosis and treatment of Alzheimer’s dementia, and only if a caregiver is available to regularly verify that the patient is taking the medicine. Diagnosis should be made according to currently accepted guidelines. The clinical benefit of this medicine and the patient’s tolerability of treatment should be reassessed regularly. This medicine may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20 mg. To minimize the risk of adverse reactions, increase the dose by 5 mg per week over the first 3 weeks as follows, until the maintenance dose is reached. Week 1 (Days 1–7): Administer 5 mg once daily for 7 days. Week 2 (Days 8–14): Administer 10 mg daily (5 mg twice daily) for 7 days. Week 3 (Days 15–21): Administer 15 mg daily (10 mg in the morning and 5 mg in the evening) for 7 days. From Week 4 onward: Administer 20 mg daily (10 mg twice daily). Maintenance dose: The recommended maintenance dose is 20 mg daily (10 mg twice daily). 2. Older adults: Based on clinical data, the recommended dose in patients 65 years of age and older is 20 mg daily (10 mg twice daily). 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-50 mL/min), the daily dose should be reduced to 10 mg. If well tolerated, the dose may be increased to 20 mg daily according to the standard dose escalation schedule after at least 7 days of treatment. In patients with severe renal impairment (creatinine clearance 5-30 mL/min), the daily dose should be reduced to 10 mg. 4. Patients with hepatic impairment: No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since no data are available on the use of memantine in patients with severe hepatic impairment, administration of this medicine is not recommended.

Precautions

This medicine should not be used in patients who are allergic to its components. It is also safe not to administer it to patients with severely impaired liver function or very poor kidney function. Caution should be exercised when using this medicine in patients with epilepsy or those who have previously experienced seizures, or have a predisposition to seizures. Concurrent use with other drugs that have similar effects may exacerbate central nervous system side effects, so combinations should be avoided. Patients with conditions where urine acidity may change or those with urinary tract infections should be closely monitored. For patients with heart disease or uncontrolled hypertension, caution is needed as the safety of this medicine has not been sufficiently established. Side effects such as dizziness, headache, constipation, drowsiness, and hypertension may appear, so symptoms should be carefully observed. As this medicine can interact with other drugs, especially antipsychotics, muscle relaxants, and anticoagulants, consultation with a doctor or pharmacist is necessary when taking these together. Women who are pregnant or may become pregnant should consult a doctor before using this medicine, and breastfeeding women are advised to discontinue breastfeeding. It is recommended not to use this medicine in children or adolescents under 18 years of age as its safety and efficacy have not been established. Overdosing on this medicine can result in central nervous system symptoms or gastrointestinal symptoms, so it is essential to adhere to the prescribed dosage and seek medical attention immediately in case of overdose. This medicine may affect reaction times, so caution is required when driving or operating machinery. Keep out of the reach of children and do not transfer the medicine to other containers, as this is important for maintaining the quality of the medicine.

Side effects

  • dizziness
  • headache
  • constipation
  • drowsiness
  • hypertension
  • fungal infection
  • confusion
  • hallucination
  • psychiatric reaction
  • gait disturbance
Show 7 more
  • seizure
  • heart failure
  • venous thrombosis/embolism
  • dyspnea
  • vomiting
  • pancreatitis
  • fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine should be stored in a tightly sealed container to prevent air or moisture from entering. It is recommended to maintain a storage temperature between 1 degree and 30 degrees Celsius. Storing it this way will safely maintain the efficacy of the medicine.

Appearance and packaging

Appearance

White oblong film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.